Business
Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development
CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced the appointment of
About this update from Onconetix, Inc.
[{"type":"text","content":"CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business Development. Mr. Jaeger brings over 25 years of biopharmaceutical experience to the BWV team, from start-up to large global pharma with significant pre-launch, launch, and in-market commercialization experience. His background in R&D, Medical Affairs, Business Development, and throughout Commercial Operations provides a broad world view and an understanding of varying perspectives. Mr. Jaeger has a wide range of specialty expertise across multiple disease areas, with substantial in-market experience on over 20 products. He is a respected industry leader and has been regularly invited to speak on commercialization topics at industry conferences and academic institutions. Mr. Jaeger was instrumental in transforming Clarus Therapeutics from R&D-focused into a commercial company. As the Senior Vice President, Chief Commercial Officer, he created a high-performing leadership team and launched its first asset – JATENZO® in just over 4 months. Despite launching into the headwinds of the pandemic, Mr. Jaeger pivoted and shifted priorities, leading Clarus through a volatile and uncertain environment, accelerated prescription growth, and received national industry recognition. During his tenure, Mr. Jaeger played key roles in taking Clarus public, helping to raise over $160 million in capital and in assisting Clarus to license two additional assets. Before joining Clarus, Mr. Jaeger held commercial leadership positions at AbbVie, including a position leading and turning around one of the largest sales teams within AbbVie’s metabolic organization. Most notably, Mr. Jaeger was responsible for the success of the Men’s Health business unit– launching AndroGel 1.62%, aligning two co-promotion partners with differing objectives, defending against two new competitive entrants, and executing innovative selling solutions. The results were clear: AndroGel doubled sales to $1.3 billion, achieved industry-leading product conversion, AndroGel 1.62% became the largest global Men’s Health product in 2011 and 2012, eclipsing Viagra, and Men’s Health became the 2nd larges...